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iral load variation in three batches of sera taken one
onth apart.
Conclusion: HCV infected haemodialysis patients expe-
ience signiﬁcant ﬂuctuation in viral load with time but no
orrelation with biochemical evidence of liver injury. HCV
enotype 1 is associated with higher viral load as compared
o genotype 3. Single-step rt qPCR assay has the potential
or rapid HCV genotyping.
oi:10.1016/j.ijid.2010.02.2003
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uns test and linear trend test of the time series of pri-
ary hepatocellular carcinoma mortality in Haimen City,
969—2007
.-X. Huang ∗, H.-B. Lu, W.-Y. Lin
Haimen City Center for Disease Prevention and Control,
iangsu Province, Haimen, China
Background: To evaluate the trend and contributing fact-
rs of time series changes of primary hepatocellular carcin-
ma (HCC) mortality between 1969 and 2007 in Haimen City.
Methods: A ﬁve-year retrospective survey was conducted
n Haimen City in 1973 to verify the cause of death among
ll city population between 1969 and 1973. The birth/death
eporting system was also established and was deﬁned as
ne of the nation’s pilot city for vital statistics by Ministry of
ealth and Ministry of Public Security. In 2006 it was accep-
ed by the International Union Against Cancer (UICC) as a
ember institute. This paper describes the time series chan-
es of HCC mortality in Haimen City between 1969 and 2007.
uns test was performed as stability test for the time series
nd linear trend test was performed as signiﬁcance test.
Results: HCC mortality increased from 33.18 per 100,000
n 1969 to 49.32 per 100,000 in 1979, with an annual increas-
ng rate of 4.04%. Between 1979 and 1989 the mortality
ncreased from 49.32 to 70.64 per 100,000, with an annual
ncreasing rate of 3.66%. Between 1989 and 1999 the mor-
ality decreased from 70.64 to 54.94 per 100,000, with an
nnual increasing rate of -2.28%. Between 1999 and 2007 the
ortality decreased from 54.94 to 50.09 per 100,000, with
n annual increasing rate of -1.15%. The runs test showed
n instable time series, and the linear trend test indicated
statistical signiﬁcant decreasing trend of HCC mortality
ince 1990. It is unlikely that this decreasing trend is caused
y random.
u
p
dternational Congress on Infectious Diseases (ICID) Abstracts
Conclusion: The decreasing trend of HCC mortality in
aimen City since 1990 is related with the intervention of
nvironmental factors including ‘changing drinking water,
hanging staple food and prevention of HBV infection’ as
ajor components.
oi:10.1016/j.ijid.2010.02.2004
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redictive factors for sustained virological response in the
reatment of patients with chronic hepatitis C
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. Mitrovic1, L. Nikitovic1, E. Gvozdenovic1, S. Zerjav1, I.
oricic2
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f Serbia, Belgrade, Serbia
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rade, Belgrade, Serbia
Background: The goal of antiviral therapy in patients with
hronic hepatitis C is to prevent progression of the dis-
ase. The most important treatment response is the absence
f viral RNA six months after discontinuation the therapy,
eﬁned as the sustained virological response (SVR). Success-
ul therapy depends on many factors that are in association
ith the virus itself and/or infected person. The aim of
he investigation was identifying some characteristics of the
atients and hepatitis C virus as pre-treatment predictive
actors for achieving SVR.
Methods: Total of 364 treatment-naïve patients was
nrolled in the study (60.4% were males; age from 16 yr-
5 yr, mean 42.18, SD± 11.71). Liver cirrhosis had 21.7%
f patients. Patients were treated with standard doses of
egylated interferon alpha and ribavirin during 6 to 12
onths depending on the genotype in the period from Jan-
ary, 2004 to January, 2009. Source of infection was blood
ransfusion, intravenous drug abuse, accidental injury and
nknown in 26.5%, 19.5%, 12%, and 42% of patients, respec-
ively. Genotype distribution revealed genotype 1, 3, and
in 56.8%, 26.7% and 5% of patients, respectively. The
inority of patients had genotype 2 and/or mixed genotypes
1b3a, 1b4). Detection and quantiﬁcation of viral RNA with
ommercial assay (Cobas Amplicor HCV Monitor v2, Roche
olecular Systems) was evaluated before treatment, after
reatment and six months later. Electronic data base (SPSS
or Windows V11.0) was used for statistical analysis.
Results: Total of 82.8% of patients were negative (HCV
NA< 50 IU/mL) after treatment while SVR was achieved
n 68.8% of patients. Binary logistic regression analysis
evealed intravenous drug abuse (p = .005) and genotype 3
p = .003) as positive, whereas age older than 40 (p = .000),
resence of cirrhosis (p = .039), and genotype 1 (p = .000)
ere negative predictor factors for SVR. In multivari-
te analysis, age older than 40 (p = .001) and genotype 1
p = .000) were signiﬁcant variables (Exp(B) = .351 vs. .233).
Conclusion: Successful virological response to therapy is
xpected in patients with genotype 3 and intravenous drug
sers. Presence of genotype 1 is the most important negative
redictor for treatment of patients with chronic hepatitis C.
oi:10.1016/j.ijid.2010.02.2005
